Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and metastasis, is a pivotal event in tumorigenesis. It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin; AstraZeneca, London, UK) is a novel and potent small-molecule inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets. This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy.
Lindsay
Colin R
CR
Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK. c.lindsay@beatson.gla.ac.uk
MacPherson
Iain Rj
IR
Cassidy
Jim
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011799:Quinazolines / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D007211:Indoles
D020533:Angiogenesis Inhibitors; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; C500926:cediranib; D007211:Indoles